www.sillajen.com Open in urlscan Pro
49.236.133.164  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Go to Contents

 * ABOUT US
     
   * Company History
     
     
   * Jennerex
     
   * Contact Us
     
   * 
   * 
   * 
 * TECHNOLOGY
   * SOLVE ®
   * GEEV ®
   * Scientific Publications
   * 
   * 
   * 
   * 
 * PIPELINE
   * Development Pipeline
   * Pexa-Vec
     (JX-594)
     
   * BAL0891
     
   * SJ-600 Series
   * JX-900 Series
   * 
 * PARTNERSHIP
   * Pexa-Vec
     Partnership
   * 
   * 
   * 
   * 
   * 
 * IR/PR
   * Notice & News
     
     
   * Stock Information
   * Financials
     
   * IR Inquiries
   * 
   * 
 * SUBSIDIARY
   * About SillaJen Biotherapeutics
   * Contact Us
   * 
   * 
   * 
   * 


SILLAJEN SITEMAP

 * ABOUT US
     
   * Company History
     
     
   * Jennerex
     
   * Contact Us
 * TECHNOLOGY
   * SOLVE ®
   * GEEV ®
   * Scientific Publications
 * PIPELINE
   * Development Pipeline
   * Pexa-Vec (JX-594)
   * BAL0891
   * SJ-600 Series
   * JX-900 Series
 * PARTNERSHIP
   * Pexa-Vec Partnership
 * IR/PR
   * Notice & News
     
     
   * Stock Information
   * Financials
     
   * IR Inquiries
 * SUBSIDIARY
   * About SillaJen Biotherapeutics
   * Contact Us

 * ENG
 * |
 * KOR

ENG
 * ENG
 * KOR


 * “A global leader in oncolytic immunotherapeutics” Targeting, Attacking, and
   Eradicating Cancers®
 * “A global leader in oncolytic immunotherapeutics” Targeting, Attacking, and
   Eradicating Cancers®
 * “A global leader in oncolytic immunotherapeutics” Targeting, Attacking, and
   Eradicating Cancers®

이전
다음

1 2 3
정지 재생

TOP


NOTICE & NEWS


SILLAJEN AND LEE'S PHARMACEUTICAL ANNOUNCE FIRST PATIENT ENROLLED IN THE PHOCUS
TRIAL IN CHINA PHASE 3 CLINICAL TRIAL FOR ONCOLYTIC IMMUNOTHERAPY, PEXA-VEC, IN
LIVER CANCER

SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS
Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in
Liver Cancer

MORE +


SILLAJEN ANNOUNCES FIRST PATIENT ENROLLED IN RENAL CELL CARCINOMA TRIAL WITH
PEXA-VEC IN COMBINATION WITH REGENERON’S CEMIPLIMAB

SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with
Pexa-Vec in Combination with Regeneron’s Cemiplimab 

MORE +


SILLAJEN POSTER PRESENTATION AT 2018 GU ASCO SYMPOSIUM HIGHLIGHTS NEW CLINICAL
DATA IN RCC, INTRAVENOUS DELIVERY OF PEXA-VEC, ONCOLYTIC IMMUNOTHERAPY

SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical
Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy 

MORE +


SILLAJEN ANNOUNCES FIRST PATIENT ENROLLED IN PART 2 OF RENAL CELL CARCINOMA
TRIAL WITH PEXA-VEC IN COMBINATION WITH REGENERON'S LIBTAYO® (CEMIPLIMAB-RWLC)



MORE +


SILLAJEN AND LEE'S PHARMACEUTICAL ANNOUNCE FIRST PATIENT ENROLLED IN THE PHOCUS
TRIAL IN CHINA PHASE 3 CLINICAL TRIAL FOR ONCOLYTIC IMMUNOTHERAPY, PEXA-VEC, IN
LIVER CANCER

SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS
Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in
Liver Cancer

MORE +


SILLAJEN ANNOUNCES FIRST PATIENT ENROLLED IN RENAL CELL CARCINOMA TRIAL WITH
PEXA-VEC IN COMBINATION WITH REGENERON’S CEMIPLIMAB

SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with
Pexa-Vec in Combination with Regeneron’s Cemiplimab 

MORE +


SILLAJEN POSTER PRESENTATION AT 2018 GU ASCO SYMPOSIUM HIGHLIGHTS NEW CLINICAL
DATA IN RCC, INTRAVENOUS DELIVERY OF PEXA-VEC, ONCOLYTIC IMMUNOTHERAPY

SillaJen Poster Presentation at 2018 GU ASCO Symposium Highlights New Clinical
Data in RCC, Intravenous Delivery of Pexa-Vec, Oncolytic Immunotherapy 

MORE +


SILLAJEN ANNOUNCES FIRST PATIENT ENROLLED IN PART 2 OF RENAL CELL CARCINOMA
TRIAL WITH PEXA-VEC IN COMBINATION WITH REGENERON'S LIBTAYO® (CEMIPLIMAB-RWLC)



MORE +


SILLAJEN AND LEE'S PHARMACEUTICAL ANNOUNCE FIRST PATIENT ENROLLED IN THE PHOCUS
TRIAL IN CHINA PHASE 3 CLINICAL TRIAL FOR ONCOLYTIC IMMUNOTHERAPY, PEXA-VEC, IN
LIVER CANCER

SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS
Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in
Liver Cancer

MORE +


SILLAJEN ANNOUNCES FIRST PATIENT ENROLLED IN RENAL CELL CARCINOMA TRIAL WITH
PEXA-VEC IN COMBINATION WITH REGENERON’S CEMIPLIMAB

SillaJen Announces First Patient Enrolled in Renal Cell Carcinoma Trial with
Pexa-Vec in Combination with Regeneron’s Cemiplimab 

MORE +




MAIN PIPELINE


PEXA-VEC

Pexa-Vec is the most advanced product candidate. Pexa-Vec is engineered to
selectively infect and replicate in cancer cells by exploiting the genetic
changes that frequently occur in cancer cells.


JX-970

JX-970 is next generation pipeline. In preclinical studies, JX-970 exerted tumor
debulking effect and the same time demonstrated selective preference for tumor
tissues.


PEXA-VEC MECHANISM OF ACTION

Pexa-Vec (JX-594)





INVESTOR RELATIONS


 * STOCK INFORMATION


 * FINANCIALS


 * FREQUENTLY ASKED
   QUESTIONS


 * IR INQUIRIES


PARTNERSHIP

 * 
 * 
 * 
   
 * 
 * 
 * 
 * 
 * 

SillaJen is actively seeking development partners and/or licensing opportunities
for all of its assets.


OFFICE


SILLAJEN HEADQUARTER

SILLAJEN HEAD OFFICE


109, Sogong-ro, Jung-gu, Seoul, Republic of Korea (ZIP Code : 04525) +82 (2)
368-2600 +82 (2) 783-7555


BUSAN OFFICE

SILLAJEN BUSAN OFFICE


6F, 111, Hyoyeol-ro, Buk-gu, Busan, Republic of Korea (ZIP Code : 46508) +82(51)
517-7550 +82(51) 517-7558


PANGYO OFFICE

SILLAJEN RESEARCH CENTER





SAN FRANCISCO OFFICE

SILLAJEN BIOTHERAPEUTICS OFFICE


SillaJen Biotherapeutics 475 Sansome St, Suite 740 San Francisco, CA 94111
+1-415-281-8886
 * Website Terms and Conditions
 * Privacy Policy
 * Unauthorized collection of email

SillaJen Head Office109, Sogong-ro, Jung-gu, Seoul, Republic of Korea (ZIP Code
: 04525)
TEL : +82 (2) 368-2600 FAX : +82 (2) 783-7555 COPYRIGHT © 2018 SillaJen, Inc.
ALL RIGHT RESERVED.